Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Preeclampsia is a major cause of illness and deaths among mothers and their babies globally. Preeclampsia is a kind of high blood pressure that occur in some women after the 20th week of pregnancy or after giving birth. This severe pregnancy disorder occurs in up to 5% of all pregnancies. It is one of the leading hypertensive disorders of pregnancy across the developed and emerging countries. It may lead to preterm birth and other complications, such as failure of organs, seizure or eclampsia, and death if it is not diagnosed at an early stage.

The Global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1,270.1 billion in 2021 and is expected to exhibit a CAGR of 11.8% during the forecast period (2021-2028).

Figure 1.Global Preeclampsia Diagnostics Market Share (%) in Terms of Value, By Product Type 2021

Preeclampsia Diagnostics  | Coherent Market Insights

Increasing prevalence of preeclampsia is expected to drive the market growth during the forecast period.

Increasing perinatal and maternal morbidity & mortality rate is set to surge the need for the early diagnosis of preeclampsia worldwide among pregnant women, which is expected to drive the global preeclampsia diagnostics market growth over the forecast period. For instance, according to the Preeclampsia Foundation, over 10 million women globally develop preeclampsia every year, and approximately 2.5 million preterm birth are caused by preeclampsia annually. The disorder is affecting both neonates and mothers in the developed and developing nations.

request-sample

Preeclampsia Diagnostics Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 1,270.1 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 11.8% 2028 Value Projection: US$ $ 2,780.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Test Type: Blood Tests, Urine Analysis, Others
  • By Product Type: Instruments, Consumables
  • By End User: Hospital, Specialty Clinics, Diagnostic Centers, Others
Companies covered:

Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.

Growth Drivers:
  • Increasing prevalence of preeclampsia 
  • Increasing launches of new product 
  • Increasing research and development for new tests to detect biomarkers indicating preeclampsia
Restraints & Challenges:
  • Lack of awareness about the preeclampsia disease

Figure 2.Global Preeclampsia Diagnostics Market Share (%), By Test Type, 2021

Preeclampsia Diagnostics  | Coherent Market Insights

Increasing product launches for preeclampsia expected to drive the market growth during the forecast period

Increasing launches of new product by key players is expected to boost the market growth during the forecast period. For instance, in February 2019, Diabetomics, is a global commercial stage medical diagnostics company announced the launch of Lumella, a rapid point-of-care test for Preeclampsia in Hyderabad, India.

Global Preeclampsia Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 212 million infected individuals worldwide as of August 24 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global preeclampsia diagnostics market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.

Global Preeclampsia Diagnostics Market: Restraint

The major factors that hinder the growth of the global preeclampsia diagnostics market include lack of awareness about the preeclampsia disease. According to a survey conducted by Progenity, Inc. in May 2021, for cause of maternal death reveals pregnant women lack awareness about preeclampsia. Nearly 30% of pregnant women in the United States experience signs and symptoms of possible preeclampsia. Approximately 5-8% of all pregnancies are complicated by preeclampsia.

Key Players

Major players operating in the global preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.

Preeclampsia is formerly known as toxemia. Preeclampsia occurs when women have high blood pressure and possibly protein in urine during pregnancy or after delivery. Preeclampsia may result in damage to the kidneys, liver, lung, heart, or eyes, and may cause a stroke or other brain injury. Preeclampsia can lead to eclampsia, a serious condition that can have health risks for both mother and baby and in rare cases can even cause death. If preeclampsia leads to seizures, then women have eclampsia. Symptoms of preeclampsia include persistent headache, abnormal swelling in hands and face, sudden weight gain, changes in vision, and pain in the right upper abdomen. The only cure for preeclampsia is to give birth. Even after delivery, symptoms of preeclampsia can last 6 weeks or more.

Market Dynamics

Key players in the market are focusing on growth strategies such as agreements, collaborations, and product launches, which are expected to drive the market growth during the forecast period. For instance, in February 2016, Diabetomics, Inc., a privately-held global medical diagnostics company, announced that the company had entered into a licensing and distribution agreement for a clinical test with BD (Becton, Dickinson and Company), a leading global medical technology company to conduct a newly developed pregnancy specific metabolic assay for the early detection of preeclampsia and gestational diabetes. In March 2015, Siemens Healthineers AG launched two new advanced urine testing solutions for the U.S. central laboratories, namely, the CLINITEK Novus Automated Urine Chemistry Analyzer and the CLINITEK AUWi PRO Automated Urine Workstation.

Key features of the study:

  • This report provides in-depth analysis of the global preeclampsia diagnostics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global preeclampsia diagnostics market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global preeclampsia diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Preeclampsia Diagnostics Market.

Detailed Segmentation:

  • Global Preeclampsia Diagnostics Market, By Test Type:
    • Blood Tests
    • Urine Analysis
    • Others
  • Global Preeclampsia Diagnostics Market, By Product Type:
    • Instruments
    • Consumables
  • Global Preeclampsia Diagnostics Market, By End User:
    • Hospital
    • Specialty Clinics
    • Diagnostic Centers
    • Others
  • Global Preeclampsia Diagnostics Market, By Region:
    • North America
      • Test Type
        • Blood Tests
        • Urine Analysis
        • Others
      • Product Type
        • Instruments
        • Consumables
      • End User
        • Hospital
        • Specialty Clinics
        • Diagnostic Centers
        • Others
      • By Country
        • U.S.
        • Canada
    • Latin America
      • Test Type
        • Blood Tests
        • Urine Analysis
        • Others
      • Product Type
        • Instruments
        • Consumables
      • End User
        • Hospital
        • Specialty Clinics
        • Diagnostic Centers
        • Others
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Test Type
        • Blood Tests
        • Urine Analysis
        • Others
      • Product Type
        • Instruments
        • Consumables
      • End User
        • Hospital
        • Specialty Clinics
        • Diagnostic Centers
        • Others
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Test Type
        • Blood Tests
        • Urine Analysis
        • Others
      • Product Type
        • Instruments
        • Consumables
      • End User
        • Hospital
        • Specialty Clinics
        • Diagnostic Centers
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Test Type
        • Blood Tests
        • Urine Analysis
        • Others
      • Product Type
        • Instruments
        • Consumables
      • End User
        • Hospital
        • Specialty Clinics
        • Diagnostic Centers
        • Others
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Test Type
        • Blood Tests
        • Urine Analysis
        • Others
      • Product Type
        • Instruments
        • Consumables
      • End User
        • Hospital
        • Specialty Clinics
        • Diagnostic Centers
        • Others
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Diabetomics, Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Thermo Fisher Scientific Inc.
    • Hoffmann-La Roche Ltd.
    • PerkinElmer Inc.
    • Siemens Healthineers AG
    • DRG INSTRUMENTS GMBH
    • Metabolomic Diagnostics Ltd.
    • Sera Prognostics
    • MOMM Diagnostics
    • Miraculins Inc.

 “*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Test Type
      • Market Snapshot, By Product Type
      • Market Snapshot, By End user
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Developments
    • Epidemiology
    • PEST Analysis
    • PORTER’s  Analysis
    • Pricing Analysis
  4. Global Preeclampsia Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic
    • Impact on Supply and Demand
    • Impact on Procedures
    • Government Initiatives
  5. Global Preeclampsia Diagnostics Market, By Test Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Blood Tests
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Urine Analysis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  6. Global Preeclampsia Diagnostics Market, By Product Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Instruments
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Consumables
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  7. Global Preeclampsia Diagnostics Market, By End User, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Hospital
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Specialty Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Diagnostic Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  8. Global Preeclampsia Diagnostics Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2028
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2017 – 2028, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Diabetomics, Inc.*
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Thermo Fisher Scientific Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Hoffmann-La Roche Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • PerkinElmer Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Siemens Healthineers AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • DRG INSTRUMENTS GMBH
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Metabolomic Diagnostics Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Sera Prognostics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • MOMM Diagnostics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Miraculins Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
    • Analyst Views
  10. Section
    • Research Methodology
    • About us

*Browse 27 market data tables and 31 figures on "Global Preeclampsia Diagnostics Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global preeclampsia diagnostics market size is estimated to be valued at US$ 1,270.1 billion in 2021 and is expected to exhibit a CAGR of 11.8 % between 2021 and 2028.
Factors such as increasing prevalence of preeclampsia, increasing launches of new products, and increasing research and development activities for new tests to detect biomarkers indicating preeclampsia are expected to drive the growth of the market during forecast period.
Blood Tests segment is expected to hold a major market share during the forecast period.
The major factor hampering the growth of the market includes lack of awareness about the preeclampsia disease.
Major players operating in the market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.